Andrew Gallimore is a British neurobiologist, chemist and pharmacologist who studies the psychedelic compound DMT and writes widely about it. He has worked at the Okinawa Institute of Science and Technology in Japan and publishes online under the name "Alien Insect." Gallimore enters the UAP conversation through his view that the beings many DMT users report meeting may be real non-human intelligences. That idea made him a frequent guest on UFO and consciousness programs in 2026.

Gallimore earned his doctorate at the University of Cambridge with a 2006 thesis on the biosynthesis of polycyclic ethers, natural compounds made by land and marine organisms. He then turned to computational neuroscience and the history of psychedelic research. His papers include a 2013 essay in the Journal of Scientific Exploration on the neuropsychological implications of DMT, a 2015 study in Frontiers in Human Neuroscience that examined the psychedelic state through integrated information theory, and a 2015 history of DMT research written with the researcher David Luke. His books are Alien Information Theory (2019), Reality Switch Technologies (2022) and Death by Astonishment (St. Martin's Press, 2025).

His best-known scientific contribution came in 2016. With the psychiatrist Rick Strassman, author of DMT: The Spirit Molecule, he published a model in Frontiers in Pharmacology showing how continuous intravenous infusion, borrowed from anesthesiology, could stretch the effect of a single DMT dose, which lasts under 20 minutes, into a stable, prolonged state. At the time the protocol had not been tested on volunteers. A 2024 study by Luan and colleagues later reported the first systematic human trial of continuous DMT infusion and cited the 2016 model as the earlier proposal. The approach, now called extended-state DMT or DMTx, is central to Gallimore's nonprofit, Noonautics. Noonautics also oversees research at Eleusis, a DMTx retreat and research center that opened on the Caribbean island of Bequia in March 2026.

Gallimore's interpretation of the drug's effects is what draws the most debate. He argues that DMT does not simply cause hallucinations but lets the brain engage with a deeper level of reality. In his view, the entities users describe are what he calls "discarnate intelligent agents." Other researchers, including Robin Carhart-Harris, treat such beings as products of the brain or the unconscious. In a June 2026 interview on The Why Files series The Basement, Gallimore described extended infusion as a way to test whether these encounters show continuity, communication and information transfer. He also discussed speculative parallels with UAP and non-human intelligence reports.

In July 2026, Gallimore and the cognitive scientist Donald Hoffman presented what they called a testable hypothesis. Under it, DMT may alter the perceptual "spacetime headset," letting people see conscious agents that are normally invisible. A related preprint, posted to PsyArXiv with Hoffman and N. Hermansson, asked whether DMT entities are real, but it has not been peer reviewed. Gallimore's significance lies in joining two roles: he co-designed an infusion method that research groups have since tested in people, and he champions the idea that DMT could be a route to contact with non-human minds.